Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 2
2018 4
2019 9
2020 8
2021 12
2022 17
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Astrocytoma, IDH-mutant, grade 3"
Page 1
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. Berger TR, et al. JAMA Oncol. 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844. JAMA Oncol. 2022. PMID: 36006639 Review.
Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocitrate dehydrogenase (IDH) mutant; oligodendroglioma, IDH mutant and 1p/19q codeleted; and glioblastoma, IDH wild …
Furthermore, the previous broad category of adult-type diffuse gliomas has been consolidated into 3 types: astrocytoma, isocit …
Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline.
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J. Mohile NA, et al. J Clin Oncol. 2022 Feb 1;40(4):403-426. doi: 10.1200/JCO.21.02036. Epub 2021 Dec 13. J Clin Oncol. 2022. PMID: 34898238
People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 should be offered RT and adjuvant TMZ. People with astrocytoma, IDH-mutant, CNS WHO grade 4 may follow recommendations for either astrocytoma …
People with astrocytoma, IDH-mutant, 1p19q non-codeleted CNS WHO grade 3 should be offered RT and adjuvan …
Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
Wong QH, Li KK, Wang WW, Malta TM, Noushmehr H, Grabovska Y, Jones C, Chan AK, Kwan JS, Huang QJ, Wong GC, Li WC, Liu XZ, Chen H, Chan DT, Mao Y, Zhang ZY, Shi ZF, Ng HK. Wong QH, et al. Mod Pathol. 2021 Jul;34(7):1245-1260. doi: 10.1038/s41379-021-00778-x. Epub 2021 Mar 10. Mod Pathol. 2021. PMID: 33692446 Free article.
We recruited a series of 67 IDH-mutant primary glioblastomas/astrocytoma IV without a prior low-grade astrocytoma and examined them using DNA-methylation profiling, targeted sequencing, RNA sequencing and TERT promoter sequencing, and correlated …
We recruited a series of 67 IDH-mutant primary glioblastomas/astrocytoma IV without a prior low-grade astrocy …
Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma.
Minniti G, Paolini S, Antonelli M, Gianno F, Tini P, Lanzetta G, Arcella A, De Pietro R, Giraffa M, Capone L, Romano A, Bozzao A, Esposito V. Minniti G, et al. J Neurooncol. 2023 Sep;164(2):331-339. doi: 10.1007/s11060-023-04418-z. Epub 2023 Sep 4. J Neurooncol. 2023. PMID: 37665475 Free PMC article.
PURPOSE: To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with temozolomide (TMZ)-based chemoradiation. ...Extent of resection, KPS, and small residual disease were associated with OS, with postoperative tu …
PURPOSE: To report the long-term outcomes in adult patients with grade 2 IDH-mutant astrocytoma treated with tem …
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ. Mohamed E, et al. Neuro Oncol. 2022 Sep 1;24(9):1471-1481. doi: 10.1093/neuonc/noac064. Neuro Oncol. 2022. PMID: 35287169 Free PMC article.
BACKGROUND: IDH-mutant diffuse gliomas are heterogeneous, and improved methods for optimal patient therapeutic stratification are needed. ...RESULTS: Tumor-specific expression of p-PRAS40, p-RPS6, and p-4EBP1 was common in IDH-mutant diffuse glioma and …
BACKGROUND: IDH-mutant diffuse gliomas are heterogeneous, and improved methods for optimal patient therapeutic stratification …
Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin.
Raghavan JV, Ganesh RA, Sonpatki P, Naik D, John AE, Arunachalam P, Shah D, P S H, Lakshmikantha A, Pillai S, Chandrachari KP, Mariswamappa K, Lale S, Shah N, Jhunjhunwala S. Raghavan JV, et al. Oncoimmunology. 2021 Aug 2;10(1):1957215. doi: 10.1080/2162402X.2021.1957215. eCollection 2021. Oncoimmunology. 2021. PMID: 34377594 Free PMC article.
Herein, we address these questions through phenotypic characterizations of monocytes and neutrophils present in blood and tumors of individuals with glioblastoma (GBM, IDH-wild type) or grade 3 IDH-mutant gliomas. We observe that neutrophils are …
Herein, we address these questions through phenotypic characterizations of monocytes and neutrophils present in blood and tumors of individu …
Correlating MRI features with additional genetic markers and patient survival in histological grade 2-3 IDH-mutant astrocytomas.
Lasocki A, Buckland ME, Molinaro T, Xie J, Whittle JR, Wei H, Gaillard F. Lasocki A, et al. Neuroradiology. 2023 Aug;65(8):1215-1223. doi: 10.1007/s00234-023-03175-0. Epub 2023 Jun 15. Neuroradiology. 2023. PMID: 37316586 Free PMC article.
This study correlated MRI features with CDKN2A/B status, IDH mutation type and survival in histological grade 2-3 IDH-mutant brain astrocytomas. METHODS: Fifty-eight grade 2-3 IDH-mutant astrocytomas were ident …
This study correlated MRI features with CDKN2A/B status, IDH mutation type and survival in histological grade 2-3 IDH- …
T2-FLAIR mismatch sign in dysembryoplasticneuroepithelial tumor.
Onishi S, Amatya VJ, Kolakshyapati M, Takano M, Yonezawa U, Taguchi A, Kaichi Y, Takeshima Y, Awai K, Sugiyama K, Kurisu K, Yamasaki F. Onishi S, et al. Eur J Radiol. 2020 May;126:108924. doi: 10.1016/j.ejrad.2020.108924. Epub 2020 Mar 2. Eur J Radiol. 2020. PMID: 32193035
PURPOSE: T2-FLAIR mismatch sign was reported as specific imaging marker in non-enhancing diffuse astrocytoma, IDH-mutant & 1p/19q non-codeleted. However, most of the previous studies for T2-FLAIR mismatch sign were confirmed only among lower grade …
PURPOSE: T2-FLAIR mismatch sign was reported as specific imaging marker in non-enhancing diffuse astrocytoma, IDH-mutant …
MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma.
Joyner DA, Garrett J, Batchala PP, Rama B, Ravicz JR, Patrie JT, Lopes MB, Fadul CE, Schiff D, Jain R, Patel SH. Joyner DA, et al. Neuroradiology. 2023 Jan;65(1):121-129. doi: 10.1007/s00234-022-03038-0. Epub 2022 Aug 12. Neuroradiology. 2023. PMID: 35953567
CONCLUSIONS: Contrast enhancement predicts WHO grade for IDH-mutant astrocytomas and oligodendrogliomas. ADC and rCBV predict WHO grade for IDH-mutant astrocytomas, but not for oligodendrogliomas....
CONCLUSIONS: Contrast enhancement predicts WHO grade for IDH-mutant astrocytomas and oligodendrogliomas. …
Impact of Frontline Ivosidenib on Volumetric Growth Patterns in Isocitrate Dehydrogenase-mutant Astrocytic and Oligodendroglial Tumors.
Kamson DO, Puri S, Sang Y, Shi MJ, Blair L, Blakeley JO, Laterra J. Kamson DO, et al. Clin Cancer Res. 2023 Dec 1;29(23):4863-4869. doi: 10.1158/1078-0432.CCR-23-0585. Clin Cancer Res. 2023. PMID: 37382607 Free PMC article.
We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib and its impact on tumor volume in IDH-mutant gliomas. EXPERIMENTAL DESIGN: We retrospectively analyzed patients ages 18 years with radiation/chemotherapy-naive, mutant IDH1, non …
We report our experience using off-label first-in-class mutant IDH1 inhibitor ivosidenib and its impact on tumor volume in IDH-mut …
72 results